作者
Maeve A Lowery, Ryan Ptashkin, Emmet Jordan, Michael F Berger, Ahmet Zehir, Marinela Capanu, Nancy E Kemeny, Eileen M O'Reilly, Imane El-Dika, William R Jarnagin, James J Harding, Michael I D'Angelica, Andrea Cercek, Jaclyn F Hechtman, David B Solit, Nikolaus Schultz, David M Hyman, David S Klimstra, Leonard B Saltz, Ghassan K Abou-Alfa
发表日期
2018/9/1
期刊
Clinical Cancer Research
卷号
24
期号
17
页码范围
4154-4161
出版商
American Association for Cancer Research
简介
Purpose: Various genetic driver aberrations have been identified among distinct anatomic and clinical subtypes of intrahepatic and extrahepatic cholangiocarcinoma, and these molecular alterations may be prognostic biomarkers and/or predictive of drug response.
Experimental Design: Tumor samples from patients with cholangiocarcinoma who consented prospectively were analyzed using the MSK-IMPACT platform, a targeted next-generation sequencing assay that analyzes all exons and selected introns of 410 cancer-associated genes. Fisher exact tests were performed to identify associations between clinical characteristics and genetic alterations.
Results: A total of 195 patients were studied: 78% intrahepatic and 22% extrahepatic cholangiocarcinoma. The most commonly altered genes in intrahepatic cholangiocarcinoma were IDH1 (30%), ARID1A (23%), BAP1 (20%), TP53 …
学术搜索中的文章
MA Lowery, R Ptashkin, E Jordan, MF Berger, A Zehir… - Clinical Cancer Research, 2018